A Phase 2 interventional study of DUR-928 Topical Solution and Vehicle Topical Solution in Plaque Psoriasis, sponsored by Durect. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Psoriasis by Bausch Health Companies Inc. — 1 open to participants now, 4 under way, none of them phase 3. Psoriasis · Bausch Health Companies Inc..
Among the 26 studies in Psoriasis by Bausch Health Companies Inc., this one is the 21st largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 22nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 26 studies in Psoriasis by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 18–99
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2007; this study’s year is marked. 3 started in 2019.
This study's enrollment of 25 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 154 across the 23 interventional studies, 394 across the 3 observational. Of the 21 that completed or were terminated, 18 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Durect, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Durect is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
1 of the studies in Psoriasis by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Psoriasis by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in subjects with plaque psoriasis. Subjects will be instructed (randomly assigned) to apply DUR-928 solution to a target lesion on one arm and vehicle solution to a target lesion on the opposite arm once daily for up to four weeks. Subjects will occlude the treated areas for approximately two hours after each application.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria assessed by the study staff may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
Drug: DUR-928 Topical Solution
Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
Drug: Vehicle Topical Solution
Topical solution containing active drug
Topical solution containing no active drug
The Change From Baseline as Assessed on the Investigator's Global Assessment (IGA) Score.
The IGA of the Target Plaques will be determined on a 5-point scale. 0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe
Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
The Change From Baseline as Assessed on the Clinical Signs of Psoriasis (Plaque Elevation, Scaling, and Erythema)
Each clinical sign (plaque elevation, scaling, erythema) will be graded on a 5-point scale.0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe.
Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
The Change From Baseline as Assessed on the Local Psoriasis Severity Index (LPSI)
The LPSI is a sum of all three parameters (sum range of 0-12, with 12 being a worse outcome). Three parameters are plaque elevation, scaling, and erythema, each rated 0-4, 0=clear to 4=severe.
Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
The Change From Baseline as Assessed by the Target Plaque Area.
The surface areas of Target Plaque A (plaque on left arm) and Target Plaque B (plaque on right arm) will be measured.
Time frame: Up to Day 57 (assessed at Baseline, and Weeks 2,4,8, change from baseline to week 4 and 8 reported)
The Change From Baseline as Assessed on the Itch Numeric Rating Scale (I-NRS) for Pruritus.
The I-NRS score is based on an 11-point scale where 0 represents "no itching" and 10 represents "worst itch imaginable."
Time frame: Up to Day 57 (assessed at Baseline, and Weeks 2,4,8, change from baseline to week 4 and 8 reported)
The Change From Baseline as Assessed on the Target Plaque Comparison
The Target Plaque Comparison is scored on a 3-point scale: 1A = Target Plaque A is better than Target Plaque B, 0 = Target Plaque A is the same as Target Plaque B, and 1B = Target Plaque A is worse than Target Plaque B.
Time frame: Up to Day 57 (assessed at Baseline, and Weeks 1,2,3,4,5,7,8, change from baseline to week 4 and 8 reported)
This was a multi-site study conducted at five sites in the United States of America. Date first subject enrolled: March 20, 2019 and date last subject completed: November 7, 2019.
| Milestone | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| Started | 25 |
| Dur-928 topical solution lesion | 25 |
| Vehicle topical solution lesion | 25 |
| Completed | 22 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 2 |
The IGA of the Target Plaques will be determined on a 5-point scale. 0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe
| score on a scale | DUR-928 Topical Solution | Vehicle Topical Solution |
|---|---|---|
| Week 4 (change from baseline) | -0.8 ± 0.83 | -1.0 ± 0.93 |
| Week 8 (change from baseline) | -0.6 ± 1.00 | -0.8 ± 1.10 |
Each clinical sign (plaque elevation, scaling, erythema) will be graded on a 5-point scale.0=Clear; 1=Almost Clear; 2=Mild; 3=Moderate; 4=Severe.
| score on a scale | DUR-928 Topical Solution | Vehicle Topical Solution |
|---|---|---|
| Week 4 (Clinical Signs of Psoriasis - Plaque Elevation-Change from Baseline) | -1.0 ± 0.88 | -1.2 ± 0.94 |
| Week 8 (Clinical Signs of Psoriasis - Plaque Elevation-Change from Baseline) | -0.7 ± 0.98 | -0.9 ± 1.06 |
| Week 4 (Clinical Signs of Psoriasis - scaling-Change from Baseline) | -0.8 ± 0.89 | -1.1 ± 1.06 |
| Week 8 (Clinical Signs of Psoriasis - scaling-Change from Baseline) | -0.6 ± 0.95 | -0.8 ± 1.18 |
| Week 4 (Clinical Signs of Psoriasis - erythema-Change from Baseline) | -1.0 ± 0.88 | -1.1 ± 1.00 |
| Week 8 (Clinical Signs of Psoriasis - erythema-Change from Baseline) | -0.9 ± 0.97 | -1.1 ± 0.97 |
The LPSI is a sum of all three parameters (sum range of 0-12, with 12 being a worse outcome). Three parameters are plaque elevation, scaling, and erythema, each rated 0-4, 0=clear to 4=severe.
| score on a scale | DUR-928 Topical Solution | Vehicle Topical Solution |
|---|---|---|
| week 4 (change from Baseline) | -2.7 ± 2.40 | -3.4 ± 2.76 |
| week 8 (change from Baseline) | -2.3 ± 2.69 | -2.8 ± 3.05 |
The surface areas of Target Plaque A (plaque on left arm) and Target Plaque B (plaque on right arm) will be measured.
| cm^2 | DUR-928 Topical Solution | Vehicle Topical Solution |
|---|---|---|
| Week 4 (change from Baseline) | -2.5 ± 11.02 | -7.4 ± 10.88 |
| Week 8 (change from Baseline) | -5.8 ± 10.26 | -8.3 ± 7.85 |
The I-NRS score is based on an 11-point scale where 0 represents "no itching" and 10 represents "worst itch imaginable."
| units on a scale | DUR-928 Topical Solution | Vehicle Topical Solution |
|---|---|---|
| Week 4 (change from baseline) | -1.7 ± 2.19 | -1.7 ± 1.84 |
| Week 8 (change from baseline) | -1.6 ± 2.34 | -1.5 ± 2.11 |
The Target Plaque Comparison is scored on a 3-point scale: 1A = Target Plaque A is better than Target Plaque B, 0 = Target Plaque A is the same as Target Plaque B, and 1B = Target Plaque A is worse than Target Plaque B.
| participants | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| Week 4 : Active Better | 2 |
| Week 4 : Same | 13 |
| Week 4 : Active Worse | 8 |
| Week 8 : Active Better | 3 |
| Week 8 : Same | 11 |
| Week 8 : Active Worse | 8 |
Collected over Up to Day 57. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DUR-928 Topical Solution and Vehicle Topical Solution, Safety Population | 0/25 (0%) | 0/25 (0%) | 11/25 (44%) |
| DUR-928 Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site. | 0/25 (0%) | 0/25 (0%) | 4/25 (16%) |
| Vehicle Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site. | 0/25 (0%) | 0/25 (0%) | 3/25 (12%) |
| Event | DUR-928 Topical Solution and Vehicle Topical Solution, Safety Population | DUR-928 Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site. | Vehicle Topical Solution, Safety Population Experiencing a TEAE at the Treatment Application Site. |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/25 | — | — |
| Application site erythemaGeneral disorders | 1/25 | 1/25 | 1/25 |
| Application site fissureGeneral disorders | 1/25 | 1/25 | 1/25 |
| Application site haemorrhageGeneral disorders | 1/25 | 1/25 | 1/25 |
| Application site injuryGeneral disorders | 1/25 | 1/25 | 0/25 |
| Application site painGeneral disorders | 1/25 | 1/25 | 1/25 |
| Application site pruritusGeneral disorders | 1/25 | 1/25 | 1/25 |
| Ear infectionInfections and infestations | 1/25 | — | — |
| Ligament sprainInjury, poisoning and procedural complications | 1/25 | — | — |
| Blood urineInvestigations | 1/25 | — | — |
Safety Population
| Age, Continuous(years) | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| Mean | 46.2 ± 11.32 |
| Sex: Female, Male(Participants) | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| Female | 10 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 22 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | DUR-928 Topical Solution and Vehicle Topical Solution |
|---|---|
| United States | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Nov 2019, 8 months.
Results were first posted in Sep 2022, 2 years 9 months after primary completion. A results delay was requested in May 2020.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Larsucosterol